Vivanza Biosciences Ltd Management Discussions

Your Directors have pleasure in presenting the Management Discussion and Analysis Report for the financial year ended 31st March, 2026.

Overview

Vivanza Biosciences Limited is engaged in the Pharmaceuticals and Agro Trading & Consultancy Activities business with a focus on delivering quality healthcare products and solutions. The Company continues to emphasize operational excellence, regulatory compliance, quality assurance, and sustainable growth. During the year under review, the Company remained committed to strengthening its business operations, enhancing customer relationships, and identifying new business opportunities while maintaining prudent financial discipline.

The Management Discussion and Analysis Report provides an overview of the industry scenario, opportunities and threats, risks and concerns, outlook, financial performance and internal control systems of the Company.

Industry Overview

The Indian pharmaceutical industry continues to be one of the fastest-growing sectors globally, supported by strong domestic demand, increasing healthcare awareness, favourable government initiatives and rising exports of pharmaceutical products. India continues to maintain its position as one of the largest suppliers of generic medicines worldwide.

The growth of the pharmaceutical sector is driven by:

- Growing healthcare expenditure and increasing health awareness.

- Expansion of healthcare infrastructure across urban and rural areas.

- Government initiatives promoting affordable healthcare and pharmaceutical manufacturing.

- Increasing demand for quality generic medicines in domestic and international markets.

- Continued investments in research, innovation and digital healthcare technologies.

Despite global economic uncertainties, geopolitical developments and pricing pressures, the Indian pharmaceutical industry continues to demonstrate resilience and offers significant long-term growth opportunities.

Opportunities and Threats

Opportunities

- Expansion of domestic and international pharmaceutical markets.

- Increasing demand for affordable healthcare products.

- Strategic collaborations and contract manufacturing opportunities.

- Adoption of digital technologies and process automation.

- Government support for the pharmaceutical manufacturing ecosystem.

Threats

- Intense competition in domestic and export markets.

- Frequent changes in regulatory requirements.

- Volatility in raw material prices and logistics costs.

- Foreign exchange fluctuations impacting export competitiveness.

- Global economic uncertainties affecting demand and supply chains.

Risk Factors and Concerns

Regulatory Risk

The pharmaceutical industry operates under stringent regulatory requirements. The Company continuously monitors changes in applicable laws and regulations and ensures compliance through established internal processes.

Market Competition

The Company operates in a highly competitive environment. Continuous product quality improvement, customer satisfaction and efficient cost management remain key focus areas to maintain competitiveness.

Supply Chain Risk

The Company monitors procurement and inventory management closely to minimize disruptions arising from fluctuations in the availability and pricing of raw materials.

Financial Risk

The Company is exposed to risks arising from changes in interest rates, credit risk and foreign exchange fluctuations. Appropriate financial controls and monitoring mechanisms are in place to manage these risks.

Internal Control Systems and Their Adequacy

The Company has an adequate system of internal financial controls commensurate with the size and nature of its business. These controls ensure safeguarding of assets, prevention and detection of frauds and errors, accuracy and completeness of accounting records and timely preparation of reliable financial information. The Audit Committee periodically reviews the adequacy and effectiveness of the internal control systems and recommends corrective actions wherever considered necessary.

Human Resources

The Company recognizes that its employees are its most valuable asset. It continues to focus on employee development through training, skill enhancement and maintaining a healthy and safe work environment. Industrial relations remained cordial throughout the financial year.

Future Outlook

The Company remains optimistic about the long-term growth prospects of the pharmaceutical industry. It will continue to focus on:

- Expanding its product portfolio.

- Strengthening operational efficiencies.

- Enhancing quality standards and regulatory compliance.

- Exploring strategic alliances and new business opportunities.

- Improving customer satisfaction and sustainable profitability.

The management remains committed to creating long-term value for all stakeholders through disciplined execution of business strategies.

DISCUSSION ON FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE

The Revenue from Operations for the financial year 2025-26 stood at Rs. 11,234.04 Lakhs, as compared to Rs. 297.74 Lakhs in the previous financial year, reflecting substantial growth in the Companys business activities.

The Company reported a Net Profit of Rs. 37.50 Lakhs during the financial year 2025-26 as against a Net Loss of Rs. 69.51 Lakhs in the previous financial year. The turnaround in profitability was primarily driven by increased business volumes, improved operational efficiency, better cost management and focused market initiatives.

The management remains committed to sustaining this growth momentum by strengthening its product portfolio, improving operational excellence, exploring new business opportunities, and creating long-term value for all stakeholders.

Place: Ahmedabad

Date: August 17, 2026

For and on behalf of the Board

For, Vivanza Biosciences Limited

Sd/-

Jayendra Mehta

Managing Director

DIN:08210602

Sd/-

Sarang Pathak

Director

DIN:02663344